Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -78.09
- Piotroski Score 1.00
- Grade Buy
- Symbol (ENSC)
- Company Ensysce Biosciences, Inc.
- Price $0.70
- Changes Percentage (27.89%)
- Change $0.15
- Day Low $0.66
- Day High $0.98
- Year High $2.06
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.16
- Trailing P/E Ratio -0.17
- Forward P/E Ratio -0.17
- P/E Growth -0.17
- Net Income $-10,613,074
Income Statement
Quarterly
Annual
Latest News of ENSC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Investing in Mensch und Maschine Software (ETR:MUM) five years ago would have delivered you a 67% gain
Stock pickers seek stocks that surpass the market. Mensch und Maschine Software's long-term performance has been strong, with a 49% share price rise in five years. However, recent gains have been mode...
By Yahoo! Finance | 1 day ago -
Is There An Opportunity With Mensch und Maschine Software SE's (ETR:MUM) 41% Undervaluation?
Analysts project a €71.17 price target for MUM, 23% below fair value. Using the DCF model, estimating Mensch und Maschine Software's intrinsic value involves predicting future cash flows and discoun...
By Yahoo! Finance | 1 month ago -
Nickelodeon's Mike O'Malley and Kirk Fogg Call 'Older Brother' Marc Summers a 'Real Mensch' During Gameshow Era
Former kids' gameshow hosts reminisced about their experiences on Nickelodeon at 90s Con, praising Marc Summers for defining the genre. They highlighted his support and influence on their careers, for...
By PEOPLE.com | 1 month ago
